NEW YORK (GenomeWeb News) – TrovaGene today said that it has licensed exclusive worldwide rights to assay technology for the detection of hairy cell leukemia.
The technology was licensed from Brunangelo Falini, a researcher at the Institute of Hematology of the University of Perugia, who published a paper earlier this year in the New England Journal of Medicine that showed that the BRAF V600E mutation was present in 100 percent of hairy cell leukemia cases studied.
San Diego-based TrovaGene said that it will offer non-exclusive licenses for diagnostic applications of the technology. The firm believes the licensed assay also will help physicians monitor the effectiveness of treatment and disease relapse.
Further terms of the licensing agreement were not disclosed.
"This new test for the diagnosis of Hairy Cell Leukemia (HCL) based on the identification of a specific BRAF gene mutation is unique in that it represents an objective, reproducible, specific, and sensitive DNA-based test for the diagnosis of HCL," Tom Adams, chairman of TrovaGene, said in a statement. "It also provides an immediate therapeutic indication for the use of available anti-B-RAF drugs."
HCL is a cancer of the bone marrow that results in accumulation of abnormal B lymphocytes in the blood. Roughly 2,000 new cases of HCL are diagnosed annually in the US and Europe.